Back to news

Axsome Therapeutics Gains as Strong Quarterly Growth and Auvelity Momentum Stay in Focus

Investivoq PriceTracker

Axsome Therapeutics (AXSM) is up 5.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears to be a continuation of investor optimism after Axsome posted strong third-quarter revenue growth and highlighted continued demand for Auvelity. This could also reflect renewed attention from this week’s investor conference appearances, which kept the company’s commercial story and pipeline milestones in focus.

Details:

  • Axsome reported third-quarter 2026 net product revenue of $259.7 million, up 52% year over year, with Auvelity sales of $207.6 million, up 53%.
  • In its November 2 business update, management pointed to sustained demand in major depressive disorder and continued acceleration of new patient initiations in Alzheimer’s disease agitation.
  • Auvelity received U.S. approval on April 30, 2026 for agitation associated with dementia due to Alzheimer’s disease, giving the product an additional growth driver beyond depression.
  • Axsome also scheduled investor events for November 9 and November 10, a backdrop that may have supported buying interest as the market revisited the recent update.

    • Sources:

    Axsome Therapeutics, SEC, Yahoo Finance

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $AXSM Insider Trading Activity

    AXSM Insider Trades

    $AXSM insiders have traded $AXSM stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.

    Here’s a breakdown of recent trading of $AXSM stock by insiders over the last 6 months:

    • HERRIOT TABUTEAU (Chief Executive Officer) has made 0 purchases and 4 sales selling 149,000 shares for an estimated $34,441,528.
    • NICK PIZZIE (Chief Financial Officer) sold 33,000 shares for an estimated $7,922,970
    • MARK COLEMAN has made 0 purchases and 4 sales selling 18,180 shares for an estimated $4,179,577.
    • MARK L. JACOBSON (Chief Operating Officer) sold 10,000 shares for an estimated $2,086,500
    • SUSAN MAHONY has made 0 purchases and 2 sales selling 600 shares for an estimated $145,017.
    • ROGER JEFFS has made 0 purchases and 2 sales selling 572 shares for an estimated $141,655.

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive AXSM Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $AXSM Hedge Fund Activity

    We have seen 274 institutional investors add shares of $AXSM stock to their portfolio, and 220 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • BLACKROCK, INC. removed 809,136 shares (-20.7%) from their portfolio in Q2 2026, for an estimated $198,052,218
    • UBS GROUP AG added 697,863 shares (+459.4%) to their portfolio in Q3 2026, for an estimated $128,678,958
    • PRICE T ROWE ASSOCIATES INC /MD/ removed 674,166 shares (-51.2%) from their portfolio in Q2 2026, for an estimated $165,015,611
    • MILLENNIUM MANAGEMENT LLC added 535,330 shares (+2578.9%) to their portfolio in Q2 2026, for an estimated $131,032,724
    • WELLINGTON MANAGEMENT GROUP LLP removed 491,386 shares (-42.9%) from their portfolio in Q2 2026, for an estimated $120,276,551
    • ADAGE CAPITAL PARTNERS GP, L.L.C. removed 478,544 shares (-64.9%) from their portfolio in Q2 2026, for an estimated $117,133,214
    • DEEP TRACK CAPITAL, LP removed 400,000 shares (-36.4%) from their portfolio in Q2 2026, for an estimated $97,908,000

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $AXSM Price Targets

    Multiple analysts have issued price targets for $AXSM recently. We have seen 3 analysts offer price targets for $AXSM in the last 6 months, with a median target of $300.0.

    Here are some recent targets:

    • Raghuram Selvaraju from HC Wainwright & Co. set a target price of $290.0 on 07/08/2026
    • Leonid Timashev from RBC Capital set a target price of $304.0 on 07/07/2026
    • Joseph Thome from TD Cowen set a target price of $300.0 on 06/17/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.